Catalyst Pharmaceuticals, Inc. plans are underway to seek approval from the FDA to increase the approved FIRDAPSE maximum daily dosage from 80mg to 100mg.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.96 USD | +1.91% | -1.29% | -11.15% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.15% | 1.73B | |
-4.66% | 87.53B | |
+1.32% | 40.42B | |
-19.07% | 29.48B | |
+57.86% | 25.43B | |
-17.58% | 11.49B | |
-43.00% | 11.3B | |
-9.14% | 11.1B | |
+5.24% | 8.75B | |
-8.42% | 7.99B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Plans Are Underway to Seek Approval from the FDA to Increase the Approved FIRDAPSE